Althea Technologies, Inc. has been selected by GeoVax Labs, Inc., an Atlanta-based biotechnology company, to manufacture its HIV-1 DNA (AIDS) vaccine for GeoVax’s Phase II trials, expected to begin in early 2008. GeoVax AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease (AIDS) caused by the HIV-1 virus by vaccinating individuals prior to the AIDS virus infection. The GeoVax vaccine regimen uses a “prime-boost strategy,” where participants receive the G...